RT Journal Article
SR Electronic
T1 First experiences with Lu-177 PSMA therapy in combination with Pembrolizumab or after pretreatment with Olaparib in single patients
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP jnumed.120.249029
DO 10.2967/jnumed.120.249029
A1 Vikas Prasad
A1 Friedemann Zengerling
A1 Jochen P Steinacker
A1 Christian Bolenz
A1 Meinrad Beer
A1 Thomas Wiegel
A1 Matthias Eiber
A1 Neil Fleshner
A1 Ambros J Beer
YR 2020
UL http://jnm.snmjournals.org/content/early/2020/11/27/jnumed.120.249029.abstract
AB Synergistic effects of immunotherapy with pembrolizumab or drugs targeting DNA damage e.g. olaparib could be used to overcome the limitations of radioligand therapy (RLT) with Lu-177 prostate specific membrane antigen (PSMA) in metastasized castrate resistant prostate cancer (mCRPC) patients. Here, we present two patients receiving such combination / sequential therapies. Methods: RLT was performed at 6-8 week intervals after they either exhausted or were considered unfit for all approved conventional treatment. Patient 1 was on pembrolizumab for his squamous cell carcinoma of the skin whereas patient 2 received RLT sequentially 4 weeks after a 3 months monotherapy with olaparib. Results: Both patients tolerated RLT without any significant hematotoxicity. Patient 2 showed radiological and biochemical response whereas patient 1 achieved PSA stabilization after 3 therapy cycles. Conclusion: These cases indicate that RLT in combination with pembrolizumab or sequentially after olaparib might be well tolerated in single patients.